We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

110 hedge funds and large institutions have $925M invested in Pliant Therapeutics in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 38 increasing their positions, 19 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more capital invested

Capital invested by funds: $241M → $925M (+$684M)

167% more funds holding in top 10

Funds holding in top 10: 3 → 8 (+5)

146% more call options, than puts

Call options by funds: $4.22M | Put options by funds: $1.71M

110% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 21

100% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 19

25% more funds holding

Funds holding: 88 → 110 (+22)

9.92% more ownership

Funds ownership: 83.32% → 93.23% (+9.9%)

Holders
110
Holders Change
+22
Holders Change %
+25%
% of All Funds
1.89%
Holding in Top 10
8
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+166.67%
% of All Funds
0.14%
New
44
Increased
38
Reduced
19
Closed
21
Calls
$4.22M
Puts
$1.71M
Net Calls
+$2.51M
Net Calls Change
+$1.03M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$52.5M
2
APM
Avidity Partners Management
Texas
+$37.9M
3
Jennison Associates
Jennison Associates
New York
+$33.3M
4
RG
Redmile Group
California
+$27.5M
5
DTC
Deep Track Capital
Connecticut
+$26.8M

Top Sellers

1
TGI
TRV GP III
Massachusetts
-$38.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$18.5M
3
SCM
Soleus Capital Management
Connecticut
-$8.97M
4
Goldman Sachs
Goldman Sachs
New York
-$6.29M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$6.23M -$719K -37,600 -11%
EP
27
Eversept Partners
New York
$6.14M +$5.63M +294,103 New
Invesco
28
Invesco
Georgia
$5.7M +$5.22M +272,667 New
Two Sigma Investments
29
Two Sigma Investments
New York
$5.18M +$4.48M +234,007 +1,671%
FIM
30
Fernwood Investment Management
Massachusetts
$4.65M +$202K +10,547 +5%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$4.5M +$2.74M +143,260 +199%
ACM
32
Altium Capital Management
New York
$4.49M +$4.11M +215,000 New
Morgan Stanley
33
Morgan Stanley
New York
$4.46M -$2.72M -142,346 -40%
State Street
34
State Street
Massachusetts
$4.46M +$2.45M +128,113 +150%
SCM
35
Silverarc Capital Management
Massachusetts
$4.38M +$4.01M +209,822 New
ACM
36
Atika Capital Management
New York
$4.07M +$3.73M +195,000 New
Millennium Management
37
Millennium Management
New York
$4.05M -$504K -26,331 -12%
Russell Investments Group
38
Russell Investments Group
United Kingdom
$4M +$3.12M +163,008 +572%
Charles Schwab
39
Charles Schwab
California
$3.53M +$1.38M +72,336 +75%
Walleye Capital
40
Walleye Capital
New York
$3.19M +$2.92M +152,741 New
BDFN
41
Bond & Devick Financial Network
Minnesota
$2.3M -$191K -10,000 -8%
EI
42
EAM Investors
California
$2.28M +$2.09M +109,220 New
AllianceBernstein
43
AllianceBernstein
Tennessee
$2.23M +$2.04M +106,671 New
Voloridge Investment Management
44
Voloridge Investment Management
Florida
$2.18M +$2M +104,307 New
CSS
45
Cubist Systematic Strategies
Connecticut
$2.14M +$982K +51,315 +100%
Goldman Sachs
46
Goldman Sachs
New York
$2.14M -$6.29M -328,658 -76%
Two Sigma Advisers
47
Two Sigma Advisers
New York
$2.1M +$869K +45,400 +82%
MIM
48
Monashee Investment Management
Massachusetts
$2.09M +$1.91M +100,000 New
Renaissance Technologies
49
Renaissance Technologies
New York
$1.97M -$207K -10,800 -10%
Federated Hermes
50
Federated Hermes
Pennsylvania
$1.67M -$4.82M -251,763 -76%
1
2
3 4 5

PLRX Hedge Fund Activity: Q3 2022 in Review

110 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2022, worth a combined $925M — up 283% from $241M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new PLRX positions and 21 closed out — a net gain of 23 holders — while 38 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $52.5M. The largest seller was TRV GP III, cutting an estimated $38.3M.

  • 110 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2022, up from 88 in Q2 2022.
  • Funds reported $925M of Pliant Therapeutics stock for Q3 2022, up 283% quarter-over-quarter.
  • 44 funds opened new Pliant Therapeutics positions in Q3 2022 and 21 closed out, a net change of +23 holders.
  • The largest Pliant Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $52.5M added.
  • The largest Pliant Therapeutics seller in Q3 2022 was TRV GP III, an estimated $38.3M sold.

Based on aggregated 13F filings for Q3 2022.